EUVIMEDTutustu EUVIMEDiin
Open access · CC BY 4.0

Development of a Brain‐Penetrant Nurr1 Agonist Tool

Jan Vietor, Tanja Stiller, Christian Gege, Wael Saeb, Úrsula López-García, Hella Kohlhof, Daniel Vitt, Daniel Merk iD

ChemMedChem · 2026-06-15 · 21 (11)

DOI: 10.1002/cmdc.70296 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-06-14. Written by Jan Vietor and 7 co-authors. Institution: Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany. Major MEDLINE topics: Nuclear Receptor Subfamily 4, Group A, Member 2, Brain, Thiophenes. 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Research Council, ERC.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

The ligand‐sensing transcription factor nuclear receptor‐related 1 (Nurr1), is thought to mediate neuroprotective activity and is implicated in various neurodegenerative diseases. Nurr1 ligands have been developed as tools to capture the receptor's potential in vitro and in vivo, but a dedicated brain‐targeting agonist has been lacking. Here, we employed the scaffold of the dihydroorotate dehydrogenase (DHODH) inhibitor and strong Nurr1 activator vidofludimus to develop a descendant with a high brain‐to‐blood ratio. Scaffold‐hopping from cyclopentene to thiophene, enhanced fluorination, and replacement of the carboxylic acid by an amide provided a highly potent, selective, and brain‐penetrant Nurr1 agonist to study the effects of Nurr1 activation in the central nervous system (CNS).

Subjects

MeSH terms (MEDLINE)

Nuclear Receptor Subfamily 4, Group A, Member 2BrainThiophenesHumansAnimalsStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugCyclopentanes

Author keywords

NR4Ablood‐brain‐barriernuclear receptor‐related 1transcription factor

Substances

Nuclear Receptor Subfamily 4, Group A, Member 2ThiophenesCyclopentanesNR4A2 protein, human

Authors and institutions

  • Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Immunic AG, Gräfelfing, Germany.
  • RebisLab R&D GmbH, Planegg-Martinsried, Germany.

ORCID profiles: Daniel Merk

Funding

  • European Research Council
  • ERC

Cite

APA

Vietor, J., Stiller, T., Gege, C., Saeb, W., López-García, Ú., Kohlhof, H., Vitt, D., & Merk, D. (2026). Development of a Brain‐Penetrant Nurr1 Agonist Tool. ChemMedChem, 21(11). https://doi.org/10.1002/cmdc.70296

Vancouver

Vietor J, Stiller T, Gege C, Saeb W, López-García Ú, Kohlhof H, et al. Development of a Brain‐Penetrant Nurr1 Agonist Tool. ChemMedChem. 2026;21(11). doi:10.1002/cmdc.70296

BibTeX
@article{Vietor2026,
  author = {Vietor, Jan and Stiller, Tanja and Gege, Christian and Saeb, Wael and López-García, Úrsula and Kohlhof, Hella and Vitt, Daniel and Merk, Daniel},
  title = {Development of a Brain‐Penetrant Nurr1 Agonist Tool},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {11},
  doi = {10.1002/cmdc.70296}
}
Start for free →